Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Afshin Gabayan, Site 0352
Toboroz
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás
Contact: Relay Therapeutics, Inc
Toboroz
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· 1/2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985· 2. fázis· Coherus Oncology, Inc.· Forrás
Toboroz
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285· 2. fázis· Puma Biotechnology, Inc.· Forrás
Contact: Puma Biotechnology, Inc. Clinical Operations Senior Director
Fut, nem toboroz
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222· 2. fázis· BioNTech SE· Forrás
Toboroz
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
NCT05733598· 2. fázis· Replimune, Inc.· Forrás
Contact: Afshin Eli Gabayan, MD
Toboroz
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· 3. fázis· Pfizer· Forrás
Toboroz
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
NCT06069570· 1. fázis· Kiromic BioPharma Inc.· Forrás
Contact: Ali Muhammad
Toboroz
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432· 1. fázis· SystImmune Inc.· Forrás
Contact: Afshin Gabayan
Fut, nem toboroz
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449· 1. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340· 3. fázis· Genentech, Inc.· Forrás
Fut, nem toboroz
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195· 4. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974· 2. fázis· Gilead Sciences· Forrás
Toboroz
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132· 1/2. fázis· Synthekine· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239· 1. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811· 2. fázis· Nuvation Bio Inc.· Forrás
Fut, nem toboroz
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499· 2/3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548· 1. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197· 3. fázis· Pfizer· Forrás